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Cholesterol-fedzebraﬁshisanemerginganimalmodeltostudymetabolic,oxidative,andinﬂammatoryvascularprocessesrelevant
to pathogenesis of human atherosclerosis. Zebraﬁsh fed a high-cholesterol diet (HCD) develop hypercholesterolemia and are
characterized by profound lipoprotein oxidation and vascular lipid accumulation. Using optically translucent zebraﬁsh larvae has
the advantage of monitoring vascular pathology and assessing the eﬃcacy of drug candidates in live animals. Thus, we investigated
whether simvastatin and ezetimibe, the principal drugs used in management of hypercholesterolemia in humans, would also
reduce cholesterol levels in HCD-fed zebraﬁsh larvae. We found that ezetimibe was well tolerated by zebraﬁsh and eﬀectively
reduced cholesterol levels in HCD-fed larvae. In contrast, simvastatin added to water was poorly tolerated by zebraﬁsh larvae
and, when added to food, had little eﬀect on cholesterol levels in HCD-fed larvae. Combination of low doses of ezetimibe and
simvastatin had an additive eﬀect in reducing cholesterol levels in zebraﬁsh. These results suggest that ezetimibe exerts in zebraﬁsh
atherapeuticeﬀectsimilartothatinhumansandthatthehypercholesterolemiczebraﬁshcanbeusedasalow-costandinformative
model for testing new drug candidates and for investigating mechanisms of action for existing drugs targeting dyslipidemia.
1.Introduction
In 2009, we suggested, for the ﬁrst time, to use zebraﬁsh as
a model organism to study speciﬁc vascular events relevant
to development of human atherosclerosis [1]. Feeding adult
zebraﬁsh a high-cholesterol diet (HCD) results in hy-
percholesterolemia, with total plasma cholesterol reaching
800mg/dL, profound lipoprotein oxidation, and formation
of vascular lesions, resembling human fatty streaks. HCD-
fed adult zebraﬁsh have been used by Cho and cowork-
ers to study eﬀects of food supplements and sweeteners
on plasma cholesterol levels and CETP activity [2–4]. The
optical transparency of zebraﬁsh larvae within ﬁrst 30 days
post fertilization (dpf) enables microscopic monitoring in
live animals of vascular lipid accumulation, recruitment of
myeloid cells, formation of macrophage foam cells, disorga-
nizationoftheendothelialcelllayer,andincreasesinvascular
PLA2 activity and vascular permeability—all induced by
a short (5–14 days) HCD feeding [1, 5]. Furthermore,
our recent report demonstrates applications of a transgenic
hsp70:IK17-EGFP zebraﬁsh, with conditional expression of
the EGFP-conjugated antibody IK17 speciﬁc to oxidized
LDL, in studying in vivo lipoprotein oxidation and in testing
therapeutic eﬀects of antioxidants [5].
Because feeding zebraﬁsh a HCD leads to extensive li-
poprotein oxidation, we further characterized the oxidized
lipid milieu in HCD-fed larvae [6]. A 2-week HCD feeding
resulted in up to 70-fold increases in the levels of oxidized
cholesterol esters, oxidized phospholipids, and lysophos-
pholipids in zebraﬁsh homogenates. Remarkably, speciﬁc
oxidized lipid molecules detected in HCD-fed zebraﬁsh
larvae using liquid chromatography-mass spectrometry were
identicaltothosefoundinhumanandmouseatherosclerotic
lesions [6]. Lipoproteins isolated from HCD-fed larvae
activated mouse macrophages in vitro, with the pattern of
ERK1/2, JNK, and Akt phosphorylation and cell spreading
similar to that induced by minimally oxidized human LDL
[6].
Thus, our work and the work of others suggest that
hypercholesterolemia and lipoprotein oxidation achieved
in zebraﬁsh and characteristics of vascular lipid accu-
mulation and inﬂammatory processes, relevant to human2 Cholesterol
atherogenesis, make the zebraﬁsh model an attractive in vivo
systemfortesting noveltherapeuticapproachesandstudying
the mechanisms of existing drugs. The goal of the present
study was to investigate whether simvastatin and ezetimibe,
the principal drugs used for management of hypercholes-
terolemia in humans, would also reduce cholesterol levels in
HCD-fed zebraﬁsh larvae.
2.MaterialsandMethods
2.1. Zebraﬁsh Maintenance and Feeding. Wild-type (AB) ze-
braﬁsh embryos were obtained by in vitro fertilization and
natural spawning of adults maintained at 28◦C on a 14/10
hour light/dark cycle and staged as described [7]. Zebraﬁsh
larvae were fed twice a day, starting at the 5th day post
fertilization (dpf), with either control diet (Golden Pearls,
100–200mm size from Brine Shrimp Direct) or HCD (4%
cholesteroldissolvedindiethyletheraddedtoGoldenPearls)
for 14 days, as described in our previous work [1]. All
animal studies were approved by the Animal Care and Use
Committee of the University of California, San Diego.
2.2. Treatment with Ezetimibe and Simvastatin. Ezetimibe
(Santa Cruz Biotechnology, cat. no. sc-205690) was added
directlytotheﬁshtankwateratconcentrationsof0.1–50µM.
This concentration range was chosen based on previous
reports that 50µM ezetimibe prevented approximately 75%
of intestinal cholesterol absorption in zebraﬁsh [8]a n do u r
preliminary studies showing a high eﬃciency of ezetimibe
at lower doses. Simvastatin (Cayman Chemicals, cat. no.
10010344) was initially added to the ﬁsh tank water, in the
samemannerasitwasdonewithezetimibe.Weobservedthat
even at low doses of simvastatin, added directly to water, it
was toxic to zebraﬁsh larvae. Thus, we changed the protocol
and mixed simvastatin into the ﬁsh food using the same
procedureasdescribedaboveformakingaHCD.Simvastatin
was added at 0.1–50µg per gram food. We estimated that
20 larvae in a ﬁsh tank consumed approximately one half of
1.5mg food administered 2 times a day. Given that larvae at
this age weigh 0.8–1.0mg, we calculated that the dose was
between 9 and 3,750ng simvastatin per mg body weight.
This translates into an equivalent of 0.6–260mg simvastatin
per 70kg body weight given to humans. Since clinical doses
of simvastatin range from 5–80mg, we consider doses of
simvastatin administered to zebraﬁsh larvae being roughly
within a therapeutic range used to treat patients. The
ezetimibe and/or simvastatin treatments described above did
not aﬀect zebraﬁsh feeding behavior, swimming pattern, nor
their growth (apparent body size).
2.3. Lipid Extraction from Zebraﬁsh Homogenates and Choles-
terol Measurements. At the end of the feeding/treatment
p e r i o d ,2 0z e b r a ﬁ s hl a r v a ei ne a c he x p e r i m e n t a lg r o u p
were euthanized by exposure to 0.05% tricaine (Sigma).
Abdomens containing undigested food were removed, and
the remaining bodies were pooled and gently homoge-
nized in 200µL of ice-cold PBS in an eppendorf tube
using a plastic pestle. After spinning down tissue debris,
the supernatant representing body ﬂuids was used for
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Figure 1: Total cholesterol levels in HCD-fed zebraﬁsh larvae.
Zebraﬁsh larvae were fed control or high-cholesterol diets starting
at the 5th dpf and continued for 14 days. Total cholesterol levels are
expressed in µg cholesterol per mg protein of larvae lysate. Mean ±
SEM from 6 independent experiments; 15–20 larvae were pooled
for each experimental data point in each individual experiment.
P<0.005.
further analysis. Protein content in the homogenates was
determined using the Bradford assay with a BCA Protein
Assay kit (Pierce). Total lipid was extracted from zebraﬁsh
homogenates as we previously described [6]. In brief, the
tissue homogenates were supplemented with 50µgs t i g -
masterol, an internal standard to control for recovery of
extracted sterols. Total lipid extraction was performed with
1:2 methanol/dichloromethane. Cholesterol esters were
saponiﬁed and total free cholesterol and stigmasterol were
measured with a Shimadzu GC-2014 gas chromatograph
using a 30m × 0.25mm (i.d.) ZB-5HT inferno capillary
column, ﬁlm thickness 0.2µm (Phenomenex). Cholesterol
and stigmasterol standards were analyzed in parallel with
experimental samples.
2.4. Statistics. Student’s t-test was used to analyze diﬀerences
between means of 2 groups. P<0.05 was used as the
signiﬁcance threshold.
3. Results and Discussion
We have previously reported that plasma cholesterol levels
in adult zebraﬁsh rise from 200 to 800mg/dL following 12
weeks of HCD feeding. Zebraﬁsh larvae are too small to
draw blood. Thus, we measured cholesterol levels in body
ﬂuids isolated from the larvae from which abdomens were
removed and remaining bodies were gently homogenized.
The homogenates were centrifuged to pellet tissue debris,
andsupernatantswereusedtoextracttotallipidandmeasure
cholesterol using a gas chromatography method. A 2-week
HCD feeding resulted in a 2.5-fold increase in cholesterol
levels in zebraﬁsh larvae (Figure 1). These results suggest
that the experimental conditions used in experiments with
zebraﬁsh larvae reported in our earlier work [1, 5, 6]l e a d
to signiﬁcant elevations in cholesterol levels in larvae bodyCholesterol 3
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Figure 2: Eﬀect of simvastatin on cholesterol levels in HCD-fed
zebraﬁsh larvae. Zebraﬁsh larvae were fed a HCD with simvastatin
mixed into zebraﬁsh food at indicated quantities (µg simvastatin
per gram food) for 14 days. Total cholesterol was measured in
lipid extracts from larvae homogenates. Values of total cholesterol
per larva were normalized to the values in the group that received
HCD only (second column). Homogenates of 20 animals were
pooled together for each data point in each individual experiment.
Experiments with 0, 10, and 50µg/g simvastatin were repeated
twice, and average values from these two experiments are presented
in the graph.
ﬂuids, comparable with hypercholesterolemia reported for
adult zebraﬁsh fed a HCD [1].
To study the eﬀect of simvastatin, we initially added it
directlytowater,asithasbeenreportedinshort-termstudies
[9]. However, we found that a prolonged exposure to sim-
vastatin in water was toxic to zebraﬁsh larvae. Varying the
doses of simvastatin and the larval age at the beginning of
treatment did not help improve zebraﬁsh survival. Next, we
mixed simvastatin into ﬁsh food at doses ranging from 0.1
to 50µg per gram of food (µg/g). As estimated in Methods, a
dose of, for example, 10µg/g simvastatin administered with
zebraﬁshfoodisroughlyanequivalentofa50mgsimvastatin
dose administered to human patients. As shown in Figure 2,
these doses of simvastatin were less eﬀective than expected
from short-term studies, with no signiﬁcant diﬀerence
between the group that received HCD alone and the group
that received HCD with higher doses of simvastatin (P =
0.11, n = 4 for the combined 10 and 50µg/g simvastatin
group). As pharmacokinetics of simvastatin administered
with food to zebraﬁsh larvae has not been explored, these
negative results could be due to a low eﬀective dose of
simvastatin. However, a higher dose is problematic given the
toxicity of simvastatin added to water.
In contrast to simvastatin, adding ezetimibe to water
did not aﬀect survival of larvae, their swimming pattern
nor apparent food intake. Based on the range of doses of
ezetimibe that has been reported to inhibit intestinal choles-
t e r o la b s o r p t i o ni nz e b r a ﬁ s hl a r v a e[ 8], we tested 0.1–50µM
ezetimibe added to water. We found that ezetimibe was
very eﬀective in reducing cholesterol levels in HCD-fed
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Figure 3: Eﬀect of ezetimibe on cholesterol levels in HCD-fed
zebraﬁsh larvae. Zebraﬁsh larvae were fed a HCD for 14 days.
Ezetimibe was added at indicated concentrations directly to ﬁsh
tank water, and the water was changed every day. Total cholesterol
was measured in lipid extracts from larvae homogenates. Values
of total cholesterol per larva were normalized to the values in the
group that received HCD only (second column). Homogenates
of 20 animals were pooled together for each data point in each
individual experiment. Experiments with 0, 1, and 5µMe z e t i m i b e
were repeated three times, and average values from these three
experiments are presented in the graph.
larvae (Figure 3). Already at the concentration of 1µM,
ezetimibe reduced cholesterol to the levels observed in larvae
fed control diet (P = 0.39 for the hypothesis that means of
“control” and “HCD +ezetimibe” are diﬀerent, n = 3).
In humans, ezetimibe targets intestinal Niemann-Pick
C1-like protein 1 (NPC1L1). The ezetimibe-binding domain
in zebraﬁsh Npc1l1 is highly homologues to the correspond-
ing domain in human NPC1L1, with preserved phenylala-
nine and methionine required for high-aﬃnity binding of
ezetimibe [8]. Larvae treated with 6.25–50µMe z e t i m i b e
shows 25–75% reductions in gallbladder formation and
in intestinal ﬂuorescence derived from nitrobenzoxadiazole
(NBD)-cholesterol [8]. These data suggest that the mech-
anism of inhibition of intestinal cholesterol absorption by
ezetimibe in zebraﬁsh is similar to that in humans, but direct
evidence of the involvement of Npc1l1 in zebraﬁsh choles-
terol metabolism targeted by ezetimibe has not yet been
reported.
Next, we tested whether a combined treatment with
ezetimibe (in water) and simvastatin (in food) would result
in greater reductions in cholesterol levels in HCD-fed larvae.
Concentrations of ezetimibe of 1 and 5µM, combined with
10 or 50µg/g simvastatin, reduced cholesterol to lower levels
than individual treatments with ezetimibe or simvastatin
(Figures 4(a), 4(b),a n d4(c)), while combinations of higher
concentrations of ezetimibe with simvastatin did not have
any additive eﬀect (Figures 4(d), 4(e),a n d4(f)). Thus, even
though simvastatin, under our experimental conditions, had
little eﬀect on cholesterol levels in zebraﬁsh larvae, selected
combinations of simvastatin with ezetimibe produced a4 Cholesterol
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Figure 4: Eﬀect of combined simvastatin and ezetimibe treatments on cholesterol levels in HCD-fed zebraﬁsh larvae. Zebraﬁsh larvae were
fed a HCD for 14 days. Simvastatin and ezetimibe were administered as described in legends to Figures 1 and 2. Total cholesterol was
measured in lipid extracts from larvae homogenates. Values of total cholesterol per larva were normalized to the values in the group that
receivedHCDonly(secondcolumn).Homogenatesof20–40animalswerepooledtogetherforeachdatapointineachindividualexperiment.
greater eﬀect in reducing cholesterol levels than each drug
alone.
Note, that in several experiments, treatments of HCD-
fed zebraﬁsh with ezetimibe or with a ezetimibe/simvastatin
combination reduced cholesterol levels as much as 4-fold
lower than in zebraﬁsh that received control diet and no
other treatment (Figures 3 and 4). Fish preferentially use
lipids rather than carbohydrates as an energy source and
would be classiﬁed, using standards applied to mammals, as
hyperlipidemic and hypercholesterolemic, even when con-
suming their normal diet [10]. Treatments with ezetimibe
a n de z e t i m i b e / s i m v a s t a t i nw e r ea b l et or e d u c e“ n o r m a l ”
zebraﬁsh hypercholesterolemia, without any apparent detri-
mental eﬀects on larvae survival, swimming pattern, or
feeding behavior.
4. Conclusions
Cholesterol feeding of zebraﬁsh larvae resulted in 2.5-fold
increases in cholesterol levels in body ﬂuids isolated from
larvae homogenates. These results agree well with our earlier
ﬁndings of elevated cholesterol levels in plasma of adult
zebraﬁsh fed a similar HCD and suggest that HCD-feeding
likely induces hypercholesterolemia in larvae as well. We
found that ezetimibe is well tolerated by zebraﬁsh larvae
and eﬀectively reduces cholesterol levels in HCD-fed larvae
to or even below the levels observed in control animals. In
contrast, simvastatin added to water is poorly tolerated by
zebraﬁsh larvae and, when added to food at the doses tested,
has little eﬀect on cholesterol levels in HCD-fed larvae.
Combination of low doses of ezetimibe and simvastatinCholesterol 5
may have an additive eﬀect in reducing cholesterol levels in
zebraﬁsh.Theseresultssuggestthat,similartoitstherapeutic
eﬀect in humans, ezetimibe eﬀectively reduces cholesterol
levels in HCD fed zebraﬁsh larvae and can be used in the
hypercholesterolemic zebraﬁsh model to study its eﬀects
on vascular lipid accumulation and inﬂammation, processes
relevant to the pathogenesis of human atherosclerosis.
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